>>> US After Hours Summary: YELP +19%, WTW +14%, GPRO +13%, ANET +12%,


After Hours Summary: YELP +19%, WTW +14%, GPRO +13%, ANET +12%, MDRX +11% higher and AAOI -27%, PI -21%, CFMS -21%, ABTL -20%, SYNA / FLR -11%, VIAB -8% lower following earnings / guidance

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings/guidance: PDLI +19.8% (also says evaluating the possibility of a new stock repurchase program), YELP +18.9% (also GrubHub and Yelp announce long-term partnership d-  GRUB to acquire Eat24), WTW +14.1%, GPRO +12.6%, ANET +12.2%, MDRX +11.4% (also Allscripts Healthcare to acquire McKesson's hospital and health system IT business, Enterprise Information Solutions, for $185 million in cash), HDP +8.8%, ETSY +8.6%, MX +7.4%, MTZ +7.1%, WING +6.3%, FIVN +6%, GEVO +5.5%, WU +4.7%, CARA +4.1%, KDMN +4%, ELY +3.8% (also Callaway Golf to acquire TravisMathew a golf and lifestyle apparel company, for $125.5 million in an all-cash transaction ), NBIX +3.2%, UNIT +2.7%, SRC +2.7% (also announced the planned spin-off of a separate publicly traded REIT), WTI +2.6%

Companies trading higher in after hours in reaction to news: AMC +2% (ticking higher; announces $100 million share repurchase program), GBT +1.5% (initiated after the close with Outperform and $53 tgt at Oppenheimer)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings/guidance: AAOI -27.4%, PI -21.3%, CFMS -20.6%, ABTL -20%, EFII -18.4%, NGVC -16.5%, CHUY -14.1%, SYNA -11%, FLR -10.6%, INFN -10.6%, CARB -9.9%, MEET -8.9%, YRCW -8.6%, MELI -8.6%, VIAB -7.6%, INFI -7.4%, BGS -7.1%, NPTN -6.5%, APPN -6.4%, GRUB -5.2% (GrubHub and Yelp announce long-term partnership - GRUB to acquire Eat24), AG -5.2%, AXDX -4.3%, INTT -4.3%, NE -4.1%, SM -3%, ATVI -1.9%, UE -1.9% (also to sell 6.25 mln common shares to Cohen & Steers)

Companies trading lower in after hours in reaction to news: DVAX -9.7% (provided regulatory update on HEPLISAV-B( following FDA Advisory Committee Meeting -- FDA requested more detailed information about the company's proposed post-marketing study for HEPLISAV-B ), APLP -7.8% (prices offering of 4 mln common units representing limited partner interests at $13.75 per common unit), AAXN -3.1% (ticking lower after Digital Ally confirmed 'yet another significant victory in its legal battles against Axon Enterprise'), BAS -1.7% (commenced at-the-market public offering of up to $50 million of its common stock pursuant to an effective shelf registration statement), DIS -1% (following VIAB results)

Optical names are pulling back following AAOI / NPTN / ACIA earnings: LITE -2.7%, OCLR -2.3%,  FNSR -1.2%, IIVI -0.6%

>>> Asian Update

Asia Mid-Session Market Update: Asia Equities trade cautiously ahead US payrolls report and Toyota earnings, USD/JPY remains near 110; RBA reiterates concerns about gains in the Aussie


***Asia Summary***
- Asian equity markets are currently trading mixed, in line with what was seen during the New York session. Overall markets have traded cautiously ahead of the later release of US monthly employment data and quarterly earnings out of auto giant Toyota.
- In Singapore, shares of large banking name DBS have declined by over 1.5% after its quarterly profits missed expectations.
- The Reserve Bank of Australia (RBA) issued its quarterly monetary policy statement in which it lowered its 2017 GDP growth forecast, but kept underlying inflation forecasts unchanged. The central bank also reiterated its concerns about the recent gains in the Australian dollar, after it suggested in its Aug 1st policy decision that the gains in the Aussie could impact growth and inflation.

***Key economic data***
- (AU) AUSTRALIA JUNE RETAIL SALES M/M: 0.3% V 0.2%E; Q/Q: 1.5% V 1.2%E
- (AU) RBA QUARTERLY STATEMENT ON MONETARY POLICY: REITERATES RECENT AUD (A$) RISE HAD MODEST EFFECT ON GDP FORECASTS
- (JP) JAPAN JUNE LABOR CASH EARNINGS Y/Y: -0.4% V 0.5%E; REAL CASH EARNINGS Y/Y: -0.8% V 0.1%E
- (PH) PHILIPPINES JULY CPI M/M: 0.3% V 0.2%E; Y/Y: 2.8% V 2.8%E; Core Y/Y: 2.1% v 2.7%e

***Speakers and Press***
Japan
- (JP) Former BoJ Official Kiuchi: Hope other members consider 'serious' policy side effect; may reach limit of JGB purchases in middle of 2018
- (JP) Japan Economic Revitalization Minister Motegi: Reiterates to maintain FY2020 primary balance surplus goal

***Asian Equity Indices/Futures (00:30ET)***
- Nikkei -0.3%, Hang Seng +0.1%, Shanghai Composite +0.2%, ASX200 -0.3%, Kospi +0.2%
- Equity Futures: S&P500 flat ; Nasdaq flat , Dax flat , FTSE100 flat

***FX ranges/Commodities/Fixed Income (00:30ET)***
- EUR 1.1869-1.1888; JPY 109.85-110.19; AUD 0.7934-0.7975; NZD 0.7423-0.7450
- Aug Gold -0.4% at 1,267/oz; Aug Crude Oil -0.4% at $48.86/brl; Sept Copper +0.3% at $2.89/lb
- GLD SPDR Gold Trust ETF daily holdings unchanged at 791.9 metric tons
- (AU) Australia sells A$500M in 1.75% Nov 2020 bonds, avg yield 1.9447%, bid to cover 5.04x
- (CN) PBOC SETS YUAN REFERENCE RATE AT: 6.7132 V 6.7211 PRIOR
- (CN) China PBOC OMO injects CNY120B in 7 and 14-day reverse repos v CNY60B in 7-day reverse repo prior

***Equities notable movers***
Australia
- Sims Metal Management, SGM.AU Announces succession plan for CEO and CFO, along with FY17 guidance; -12.7%
- Commonwealth Bank, CBA.AU Austrac initiated civil penalty proceedings related to anti-money laundering and counter-terrorism financing laws
- Crown Ltd, CWN.AU FY17 profits below estimates; -2%
- Tabcorp, TAH.AU Reported FY17 results; +1.3%

Hong Kong/China
- CK Hutchsion Holdings, 1.HK H1 Profits below estimates; -4.5%

Japan
- Mazda, 7261.JP Speculated capital tie-up with Toyota; +4.5%

***US markets on close: Dow flat, S&P500 -0.2%, Nasdaq -0.4%, Russell -0.6% ***
- Best Sector in S&P500: Utilities, Industrials +0.5%
- Worst Sector in S&P500: Energy -1.4%
- At the close: VIX 10.44 (+0.16 pts); Treasuries: 2-yr 1.34% (-2bps), 10-yr 2.22% (-5bps), 30-yr 2.79% (-6bps)

***US Market Summary***
- Blue chips continued to hit higher ground, with the Dow marking a new all-time high again at 22,040 before trading lower towards day end. Apple and Amazon both lost nearly 1%, putting the most pressure on the S&P. Attention shifts to tomorrow's jobs data. Yesterday's lower than expected ADP weekly increase reduced forecasts for tomorrow's NFP data, with consensus at +178k.

***US Afterhours Movers***
-After Market Movers
-GPRO Reports Q2 -$0.09 v -$0.26e, Rev $296.5M v $271Me; Guides Q3 R$290-310M v $279Me, Gross Margin 36-38% range; +16% afterhours
-YELP Reports Q2 $0.25 v $0.20e, Rev $208.9M v $205Me; authorizes $200M share buyback; +14.8% afterhours
-WTW Reports Q2 $0.67 v $0.50e, Rev $341M v $334Me; Raises FY17 $1.57-1.67 v $1.28e (prior FY17 $1.40-1.50); +14.3% afterhours
-MDRX Reports Q2 $0.15 v $0.15e, Rev $428M v $424Me; Raises FY17 R$1.79-1.82B v 1.72Be; +12.2% afterhours
-FLR Reports Q2 -$0.17* v $0.59e, Rev $4.70B v $4.94Be; -9.0% afterhours
-SYNA Reports Q4 $1.18 v $1.16e, Rev $426.5M v $427Me; Guides Q1 Rev $380-420M v 447Me; -14.6% afterhours
-PI Reports Q2 $0.06 v $0.03e, Rev $34.1M v $33.9Me; Guides Q3 -$0.08 to -$0.01 v $0.08e, R$31.8-33.3M v $38Me, Adj EBITDA -$1.7M to -$0.2M ; -23.3% afterhours
-AAOI Reports Q2 $1.54 v $1.35e, Rev $117.4M v $116Me; Guides Q3 $1.30-1.43 v $1.36e; R$107-115M v $123Me; Sees softer than expected demand for 40G solutions with a large customer; -29.3% afterhours

>>> US Close Dow +0,04% S&P -0,22% Nasdaq -0.35% Russell -0.54%

Closing Market Summary: Stocks Tick Lower on Thursday

Equities ticked down on Thursday, sending the S&P 500 and the Nasdaq lower by 0.2% and 0.4%, respectively. However, the Dow (unch) managed to eke out yet another record close, its seventh in a row.

The energy sector tumbled 1.3% on Thursday in its worst one-day performance since July 6. Just about all energy components finished in negative territory with Dow component Chevron (CVX 109.43, -1.03) dropping 0.9%. Crude oil held a gain of around 0.7% in the morning session, but dropped sharply around midday. WTI crude settled lower by 0.7% at $49.26/bbl.

In total, seven of the eleven sectors settled in negative territory. The top-weighted technology (-0.4%) and financials (-0.5%) sectors struggled to keep pace with the broader market throughout the day. The lightly-weighted materials space (-0.7%) also exhibited relative weakness while the remaining laggards finished with losses of no more than 0.3%.

At the opposite end of the leaderboard, the health care (+0.2%), industrials (+0.5%), utilities (+0.4%), and telecom services (unch) groups finished with modest victories. Aetna (AET 158.54, +3.80) helped keep the health care group afloat, climbing 2.5% after beating both top and bottom line estimates and raising its guidance for the fiscal year.

Transports were among the top performers in the industrial sector, pushing the Dow Jones Transportation Average higher by 0.3%. Dow components General Electric (GE 25.76, +0.24) and 3M (MMM 207.62, +2.21) also outperformed, adding 0.9% and 1.1%, respectively.

Meanwhile, the rate-sensitive utilities group benefited from broad strength as a rally in the Treasury market left interest rates lower across the yield curve; the benchmark 10-yr yield dropped four basis points to 2.23% while the 2-yr yield slipped two basis points to 1.34%.

The Treasury market moved higher after the Bank of England voted 6-2 in favor of holding the key rate at 0.25% and lowered the UK's 2017 GDP growth forecast to 1.7% from 1.9%. The previous BoE meeting featured three calls for a rate hike, but, despite the slight change in voting, the Monetary Policy Committee noted that the key rate may need to rise more than the market currently expects.

In the currency market, the U.S. dollar climbed 0.6% against the British pound to 1.3144, but the U.S. Dollar Index (92.62, -0.13) still finished lower by 0.1% as the Japanese yen showed relative strength (109.99, -0.6%). The U.S. Dollar Index settled at a 15-month low.

Reviewing Thursday's economic data, which included the weekly Initial Claims Report, June Factory Orders, and the July ISM Services Index:

  • The latest weekly initial jobless claims count totaled 240,000 while the consensus expected a reading of 242,000. Today's tally was below the revised prior week count of 245,000 (from 244,000). As for continuing claims, they increased to 1.968 million from the revised count of 1.965 million (from 1.964 million).
    • The key takeaway from the report is that initial claims were in-line with their longstanding trend of signaling a tight labor market.
  • The Factory Orders Report for June showed an increase of 3.0%, which is above the consensus of 2.9%. The May reading was revised to -0.3% (from -0.8%).
    • The key takeaway from the report is that order activity outside the transportation sector was relatively weak in June. Nondefense capital goods orders, excluding aircraft -- a proxy for business spending -- were unchanged in June.
  • The ISM Services Index for July declined to 53.9 from an unrevised reading of 57.4 in June. The consensus expected a reading of 56.9.
    • The key takeaway from the report is that the non-manufacturing sector's expansion saw a notable deceleration in July, which isn't an uplifting consideration as it relates to the third quarter growth outlook. According to the ISM, the past relationship between the NMI and the overall economy indicates the NMI for July corresponds to a 1.9% increase in real GDP on an annualized basis.

On Friday, investors will receive the Employment Situation Report for July at 8:30 ET. Economists polled by expect the jobs report to show the addition of 181,000 nonfarm payrolls, an unemployment rate of 4.3%, and an increase of 0.3% in average hourly earnings.

The only other report on Friday's economic calendar is the June Trade Balance (consensus -$44.9 billion), which will also be released at 8:30 ET.

  • Nasdaq Composite +17.8% YTD
  • S&P 500 +10.4% YTD
  • Dow Jones Industrial Average +11.5% YTD
  • Russell 2000 +3.5% YTD

FT : Icarus — amazing viewing

Icarus — amazing viewing --> Trailer :

An enthralling documentary that lifts the lid on drug use in sport

Icarus may be the best nonfiction movie of the year. Bryan Fogel’s film about drug use in sport was praised at Sundance, then bought by Netflix in a record deal for a documentary. $4m: easy to see why. The film is a corker. Or an un-corker — of chastising yet cathartic truths. Though it can’t be seen in theatres, it should be sought and seen anyway. And anywhere.

As a Sundance reviewer rightly noted, the film starts like Morgan Spurlock and ends like Laura Poitras. At the beginning Fogel is filmmaker-as-guinea-pig, supersizing his athletic prowess to enter an international bike race under a performance-enhancing drugs regime (chronicled as it goes). By mid-movie he is in CitizenFour mode, sheltering and interviewing real-life defector Grigory Rodchenkov, the one-time anti-doping chief in Russian sport.

Holed up in Shakicam City — let’s bestow that name on Bryan and Grigori’s succession of secret apartments and hotel rooms, shot with handheld cameras — they blow the cover on a drug scandal that ascends to Putin. Rodchenkov is a showboating stick of nerves with a pot belly and greying Chaplin ’tache. In idiomatic English he says, “I could be tossed to the bus any time.”

He could. Back in Russia he attempted suicide. He has now left behind his children and wife, fleetingly glimpsed on Skype. His and Fogel’s account of the lengths to which a country went to “game the system” makes amazing viewing — and listening. Early summarisation by Rodchenkov: “The system in place to test athletes . . . was bullshit.” By most of the evidence, Icarus makes clear, and God knows makes enthralling, it probably still is.

FT : Statins are worth the risks for most patients

Statins are worth the risks for most patients

As more people are prescribed the medication, it is coming under wider scrutiny


Even if you don’t take a statin now, it might not be long before you do. The pills, which lower the levels of harmful cholesterol (low-density lipoprotein, or LDL) associated with heart disease and strokes, constitute the most commonly prescribed class of drugs in the UK. They work by disrupting the production of cholesterol in the liver.

As their ubiquity grows, so does the controversy surrounding them. A minority of people, especially women, report side effects such as muscle pain. This week, a paper was published exploring the implications of the National Institute for Health and Care Excellence (Nice) cholesterol guidelines, which recommend statin therapy for anyone with a 10 per cent risk of developing cardiovascular disease (CVD) within the next 10 years.


If these guidelines were followed to the letter in England, according to the paper in the British Journal of General Practice, then an astonishing 11.8m people aged between 30 and 84 would be eligible for statins.

Actually, it becomes less astonishing when you realise that Nice’s risk threshold folds in pretty much all men over 60 and all women over 75, regardless of existing health and lifestyle factors. England, like the rest of the UK, has an ageing population — and one of the biggest predictors of CVD is age.

What is more interesting is that about 9.8m of them have never had a heart attack or stroke. Many of those as-yet-unafflicted folk are likely to sail through another decade without cardiovascular incident. Given the possibility of side-effects, says the Royal College of General Practitioners, dispensing statins so prodigiously would end up with people being needlessly medicalised and possibly even harmed.


The college took particular aim at the way CVD risk is calculated, using an algorithm called QRISK. In response to the paper, Professor Helen Stokes-Lampard, chair of the RCGP, said: “We need to get the risk scores right. If we find that all men over 60 and all women over 75 are going to be eligible for statins with new risk scoring, regardless of any other risk factor, then it should ring alarm bells — because it is not clear that every 60-year-old man or 75-year-old woman is going to benefit from statin therapy.”

As well as warning of the dangers of over-treatment, she pointed out the extra NHS workload and expense that might accrue from people sprinting to their doctors for a prescription.

An almost identical debate about risk and treatment guidelines is happening in the US. The American College of Cardiology, together with the American Heart Association, sets the bar at a 7.5 per cent risk over 10 years. The US Preventive Services Task Force, an influential government-appointed panel that reviews clinical evidence, issued more stringent recommendations last year. Statins, it concluded, best served those who had a 10 per cent risk and another qualifying condition, such as diabetes or hypertension.

Opting for statins means making a commitment to take a daily medicine for the rest of one’s life. The decision lies with the patient, usually in discussion with his or her GP. But the estimate of an individual’s risk is a different issue from whether statins actually work. So, we might usefully ask: do they deliver clinically meaningful benefits?

According to a major review published last year in The Lancet, the answer is a resounding yes. For every 10,000 people on an average dose of 40mg for five years, around 1,000 people with existing diagnoses are protected against further heart attacks and stroke (so-called secondary prevention). Further, the review suggests 500 people are protected from having their first incident (primary prevention).

What of the side effects? The same regimen would produce up to 100 new cases of diabetes, around five cases of myopathy (muscle weakness; this can, rarely, lead to severe complications), and up to 10 haemorrhagic strokes (strokes resulting from an internal bleed). Professor Rory Collins, from the University of Oxford, who led this review, concluded that the benefits of statins had been underestimated and the side-effects overplayed.

Interestingly, the link between statins and muscle pain — widely reported in the media — partially evaporates on closer inspection. In May, another study in The Lancet comparing the frequency of adverse events during different sorts of clinical trials showed that patients seemed to be heavily influenced by negative expectations of the drug: a large proportion of those reporting muscle pain were actually on a placebo, rather than the statin. This fascinating phenomenon, known as the nocebo effect, suggests that, out in the real world, some ailments, though genuine, are incorrectly attributed to statins.

Prof Collins, a vocal public champion of statins, doesn’t have it all his own way. In March, Dr Fiona Godlee, editor of the British Medical Journal, argued that there are still uncertainties relating to the health benefits of statins for those unaffected by CVD.

She also points out that much of the data on which Prof Collins based his positive review came from industry sponsors and is not available for independent, outside scrutiny. Dr Godlee asks: “Why . . . should statins be singled out in calls for independent review of the raw data? Because they are already the most widely prescribed class of drug in high-income and middle-income countries, and because proposals for even wider prescription have sparked justifiable controversy . . . when unabridged internal clinical study reports containing anonymised patient-level data are scrutinised by fresh expert eyes, new information and uncertainties emerge . .. ”

There may be good reasons, other clinicians say, for a person aged over 75 who has never had CVD to be wary of statins: they might be coping with other illnesses and on multiple drugs already (the more medicines a patient takes, the higher the risk of harmful drug interactions). Dissenting voices counter that since statins confer long-term benefit, people are better off starting them preemptively.

The non-industry StaREE (Statins for Reducing Events in the Elderly) trial in Australia will report on exactly this patient group — over-75s without CVD — in 2020. While statins undoubtedly benefit those already suffering, the therapy’s effectiveness among low-risk groups — who can also change their lifestyle in pursuit of health — remains a live question.


Heart health and algorithms

Anyone can look up the QRisk calculator and check out their own score (it is only valid for those in the UK who have not had a diagnosis of coronary heart disease or stroke).
I used the newest version, called QRisk3. After entering information about my age, gender and ethnicity, I was assigned a 3.8 per cent risk of developing cardiovascular disease during the next decade (there were other questions, too, about blood pressure and cholesterol levels, which I left blank).
It is a newer, more detailed version of QRisk2, which led to Nice revising the risk threshold downwards from 20 per cent to 10 per cent. That second iteration in 2014 swept many more people into the remit of statins, prompting widespread discussion about the medicalisation of society.